H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Jeffrey S. Weber, MD, PhD

Jeffrey S. Weber, MD, PhD

Faculty Rank:

Senior Member

Titles:

  • Director, Donald A. Adam Comprehensive Melanoma Research Center

Department/Program Affiliations:

  • Cutaneous Oncology  
  • Immunology  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Office:

(813) 745-2007

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences
  • Medicine / Internal Medicine

University Academic Rank:

Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jeffrey S. Weber, MD, PhD

Education & Training:

  • Fellow, National Cancer Institute, 1990 - Surgery Branch, Tumor Immunology
  • Fellow, National Cancer Institute, 1988 - Surgery Branch, Tumor Immunology
  • Fellow, National Cancer Institute, 1986 - Medicine Branch
  • Residency, University of California, 1983 - Medicine
  • Internship, University of California, 1981 - Medicine
  • MD, New York University Medical Center, 1980
  • PhD, Rockefeller University, 1979 - Molecular Cell Biology

General Board Certification / SubSpecialty:

  • Internal Medicine / Medical Oncology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jeffrey S. Weber, MD, PhD

Research Interests:

My research interests lie in the monitoring and characterization of T cell responses to vaccination in cancer patients, and in the establishment of in vitro models to facilitate the understanding of how immune modulating antibodies amplify T cell responses in patients. I am also interested in the mechanisms by which achieving autoimmunity induces regression of cancer.


Clinical Interests:

My clinical interests are in the immunotherapy of melanoma and other malignancies, with a focus on vaccines, adoptive immunotherapy, dendritic cell therapy and the use of immune modulating antibodies.

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jeffrey S. Weber, MD, PhD

Publications:

  1. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2010 Jan;. Pubmedid: 20082117.   Pubmed ID: 20082117

  2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb? C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug;363(8):711-723. Pubmedid: 20525992.   Pubmed ID: 20525992

  3. Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersh E, Richards J, Weber JS, Hoon DS. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr;16(8):2402-2408. Pubmedid: 20371696.   Pubmed ID: 20371696

  4. R?ttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, Weber JS. Immunotherapy of cancer: key findings and commentary on the Third Tegernsee Conference. Oncologist. 2010 Jan;15(1):112-118. Pubmedid: 20061401.   Pubmed ID: 20061401

  5. Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug;116(15):3683-3691. Pubmedid: 20564083.   Pubmed ID: 20564083

  6. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR Imaging Findings. AJNR Am J Neuroradiol. 2009 Oct;30(9):1751-1753. Pubmedid: 19474123.   Pubmed ID: 19474123

  7. O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS. Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients With metastatic melanoma. J Clin Oncol. 2009 Dec;27(36):6207-6212. Pubmedid: 19917850.   Pubmed ID: 19917850

  8. Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 2009 May-Jun;15(3):169-173. Pubmedid: 19556898.   Pubmed ID: 19556898

  9. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009 May;24(5):643-650. Pubmedid: 19283671.   Pubmed ID: 19283671

  10. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. Int Immunol. 2009 Sep;21(9):1065-1077. Pubmedid: 19651643.   Pubmed ID: 19651643

  11. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009 Sep;15(17):5591-5598. Pubmedid: 19671877.   Pubmed ID: 19671877

  12. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009 May;58(5):823-830. Pubmedid: 19198837.   Pubmed ID: 19198837

  13. Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 2009 Sep;115(17):3944-3954. Pubmedid: 19536884.   Pubmed ID: 19536884

  14. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb? C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res. 2009 Dec;15(23):7412-7420. Pubmedid: 19934295.   Pubmed ID: 19934295

  15. Zager JS, Weber JS. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II. Cancer Control. 2009 Jul;16(3):196-197. Pubmedid: 19556959.   Pubmed ID: 19556959

  16. McLoughlin J, Melis M, Siegel E, Dean E, Weber J, Chern J, Elliott M, Kelley S, Karl R. Are patients with esophageal cancer who become PET negative after neoadjuvantchemoradiation free of cancer. J Am Coll Surg. 2008 May;206(5):879-886. Pubmedid: 18471715.   Pubmed ID: 18471715

  17. Phan G, Weber J, Sondak V. CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer :Surgical Issues. Ann Surg Oncol. 2008 Nov;3014(3021). Pubmedid: 18716842.   Pubmed ID: 18716842

  18. Thompson J, Curti B, Redman B, Bhatia S, Weber J, Agarwala S, SieversEL, Hughes S, Devries T, Hausman D. Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanom and Renal Cell Carcinoma. J Clin Oncol. 2008 Apr; 26(12):2034-2039. Pubmedid: 18347008.   Pubmed ID: 18347008

  19. Weber J, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma. J Clin Oncol. 2008 Dec;26(36):5950-5956. Pubmedid: 19018089.   Pubmed ID: 19018089

  20. Weber J. Introduction: Immune-modulating antibodies. Oncologist. 2008;13:1-1. Pubmedid: 19001144.   Pubmed ID: 19001144

  21. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008 13 ;13:16-25. Pubmedid: 19001147.   Pubmed ID: 19001147

  22. Weber J. Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma. J Invest Dermatol. 2008 Dec;128(12):2750-2752. Pubmedid: 18997841.   Pubmed ID: 18997841

  23. Brinkman J, Hughes S, Stone P, Caffrey A, Muderspach L, Roman L, Weber JS, Kast W. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers. 2007;23(4):337-352. Pubmedid: 17627067.   Pubmed ID: 17627067

  24. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007 May;4(5):e176-. Pubmedid: 17488182. Pmcid: PMC1865558.   Pubmed ID: 17488182

  25. Hamid O, Solomon J, Scotland R, Garcia M, Sian S, Ye W, Groshen S, Weber JS. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007 Jan;13(1):215-222. Pubmedid: 17200357.   Pubmed ID: 17200357

  26. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007 Jul;12(7):864-872. Pubmedid: 17673617.   Pubmed ID: 17673617

  27. Wong R, Scotland R, Lau R, Wang C, Korman A, Kast W, Weber J. Programmed death-1 blockade enhances expansion and functional capacity of humanmelanoma antigen-specific CTLs. Int Immunol. 2007 Oct;19(10):1223-1234. Pubmedid: 17898045.   Pubmed ID: 17898045

  28. Koh YT, Higgins SA, Weber JS, Kast WM. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med. 2006 Oct;4:42-42. Pubmedid: 17059610.   Pubmed ID: 17059610

  29. Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown Pp, Davis MM. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med. 2005 Oct;2(10):e265-e265. Pubmedid: 16162034.   Pubmed ID: 16162034

  30. Lewis K, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, BaronA, Russ P, Gonzalez R. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005 Nov;23(4):303-308. Pubmedid: 16100942.   Pubmed ID: 16100942

  31. Liu D, O'Day S, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res. 2005 Feb;11(3):1237-1246. Pubmedid: 15709194.   Pubmed ID: 15709194

  32. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, NicholG, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005 Feb;23(4):741-750. Pubmedid: 15613700.   Pubmed ID: 15613700

  33. Chiong B, Wong R, Lee P, Delto J, Scotland R, Lau R, Weber J. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine. J Immunother (1997). 2004 Sep;27(5):368-379. Pubmedid: 15314545.   Pubmed ID: 15314545

  34. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004 Nov;1(2):e28-e28. Pubmedid: 15578105.   Pubmed ID: 15578105

  35. Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C, Weber J. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res. 2004 Aug;10(15):5004-5013. Pubmedid: 15297401.   Pubmed ID: 15297401

  36. Xu T, Shu C, Purdom E, Dang D, Ilsley D, Guo Y, Weber J, Holmes S, LeePP. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res. 2004 May;64(10):3661-3667. Pubmedid: 15150126.   Pubmed ID: 15150126

  37. Aparicio A, Eads C, Leong L, Laird P, Newman E, Synold T, Baker S, Zhao M, Weber J. Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol. 2003 Mar;51(3):231-239. Pubmedid: 12655442.   Pubmed ID: 12655442

  38. Koya R, Kasahara N, Favaro P, Lau R, Ta H, Weber J, Stripecke R. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother (1997). 2003 Sep;26(5):451-460. Pubmedid: 12973034.   Pubmed ID: 12973034

  39. Pullarkat V, Lee P, Scotland R, Rubio V, Groshen S, Gee C, Lau R, SnivelyJ, Sian S, Woulfe S, Wolfe R, Weber J. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003 Apr;9(4):1301-1312. Pubmedid: 12684398.   Pubmed ID: 12684398

  40. Rubio V, Stuge T, Singh N, Betts M, Weber J, Roederer M, Lee P. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003 Nov;9(11):1377-1382. Pubmedid: 14528297.   Pubmed ID: 14528297

  41. Tagawa S, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, HickingbottomB, Smith J, Johnson D, Weber J. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003 Jul;98(1):144-154. Pubmedid: 12833467.   Pubmed ID: 12833467

  42. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, II Smith W, Dutcher P, Gollob J, Longmate J, Johnson D. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002 Apr;128(4):214-218. Pubmedid: 11935312.   Pubmed ID: 11935312

  43. Pullarkat V, Lau R, Lee S, Bender J, Weber J. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods. 2002 Sep;267(2):173-183. Pubmedid: 12165439.   Pubmed ID: 12165439

  44. Silverman M, Hedley M, Petry K, Weber J. Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. J Low Genit Tract Dis. 2002 Oct;6(4):206-211. Pubmedid: 17051023.   Pubmed ID: 17051023

  45. Weber J. Peptide vaccines for cancer. Cancer Invest. 2002 20(;20(2):208-221. Pubmedid: 11901542.   Pubmed ID: 11901542

  46. Yu C, Chen J, Apuzzo M, O'Day S, Giannotta S, Weber J, Petrovich Z. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002 Apr;52(5):1277-1287. Pubmedid: 11955740.   Pubmed ID: 11955740

  47. Atkins M, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson B, Plasse T. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res. 2001 Mar;7(3):486-492. Pubmedid: 11297238.   Pubmed ID: 11297238

  48. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback M, Weber J. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother (1997). 2001 Jan;24(1):66-78. Pubmedid: 11211150.   Pubmed ID: 11211150

  49. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol. 2001 Sep;19(18):3836-3847. Pubmedid: 11559721.   Pubmed ID: 11559721

  50. Margolin K, Longmate J, Synold T, Gandara D, Weber J, Gonzalez R, Johansen M, Newman R, Baratta T, Doroshow J. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs. 2001 Aug;19(4):335-340. Pubmedid: 11561695.   Pubmed ID: 11561695

  51. Weber J, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol. 2001 Mar;13(2):124-128. Pubmedid: 11224710.   Pubmed ID: 11224710

  52. Weber J, Mule J. How much help does a vaccine-induced T-cell response need. J Clin Invest. 2001 Mar;107(5):553-554. Pubmedid: 11238555.   Pubmed ID: 11238555

  53. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small L, Kast W, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000 Sep;6(9):3406-3416. Pubmedid: 10999722.   Pubmed ID: 10999722

  54. Kuniyoshi J, Kuniyoshi C, Lim A, Wang F, Bade E, Lau R, Thomas E, Weber J. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol. 1999 Apr;193(1):48-58. Pubmedid: 10202112.   Pubmed ID: 10202112

  55. Lee P, Yee C, Savage P, Fong L, Brockstedt D, Weber J, Johnson D, Swetter S, Thompson J, Greenberg P, Roederer M, Davis M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun;5(6):677-685. Pubmedid: 10371507.   Pubmed ID: 10371507

  56. Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber J. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother. 1999 Apr;48(1):9-21. Pubmedid: 10235484.   Pubmed ID: 10235484

  57. Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang J, Linehan W, Rosenberg S. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998 Mar;159(3):718-722. Pubmedid: 9474133 .   Pubmed ID: 9474133

  58. Mule J, Custer M, Averbook B, Yang J, Weber J, Goeddel D, Rosenberg S, Schall T. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996 Aug;7(13):1545-1553. Pubmedid: 8864755 .   Pubmed ID: 8864755

  59. Heywood G, Rosenberg S, Weber J. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst. 1995 Jun;87(12):915-922. Pubmedid: 7666481 .   Pubmed ID: 7666481

  60. Yang J, Topalian S, Schwartzentruber D, Parkinson D, Marincola F, Weber J, Seipp C, White D, Rosenberg S. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 1995 Aug;76(4):687-694. Pubmedid: 8625167 .   Pubmed ID: 8625167

  61. Cole D, Sanda M, Yang J, Schwartzentruber D, Weber J, Ettinghausen S, Pockaj B, Kim H, Levin R, Pogrebniak H, et a. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J Natl Cancer Inst. 1994 Jan;86(1):39-45. Pubmedid: 8271281 .   Pubmed ID: 8271281

  62. Guleria A, Yang J, Topalian S, Weber J, Parkinson D, MacFarlane M, White R, Steinberg S, White D, Einhorn J, et a. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994 Dec;12(12):2714-2722. Pubmedid: 7989949 .   Pubmed ID: 7989949

  63. Kim H, Rosenberg S, Steinberg S, Cole D, Weber J. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):60-65. Pubmedid: 8081560 .   Pubmed ID: 8081560

  64. Mastorakos G, Weber J, Magiakou M, Gunn H, Chrousos G. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab. 1994 Oct;79(4):934-939. Pubmedid: 7962300 .   Pubmed ID: 7962300

  65. Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D, Seipp C, Einhorn J, White D. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama. 1994 Mar;271(12):907-913. Pubmedid: 8120958 .   Pubmed ID: 8120958

  66. Salgaller M, Weber J, Koenig S, Yannelli J, Rosenberg S. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 1994 Aug;39(2):105-116. Pubmedid: 7519125 .   Pubmed ID: 7519125

  67. Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg S. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol. 1994 May;15(4):292-302. Pubmedid: 7520334 .   Pubmed ID: 7520334

  68. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg S. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 1994 Apr;54(7):1766-1771. Pubmedid: 7511051 .   Pubmed ID: 7511051

  69. Yang J, Topalian S, Parkinson D, Schwartzentruber D, Weber J, Ettinghausen S, White D, Steinberg S, Cole D, Kim H, et a. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994 Aug;12(8):1572-1576. Pubmedid: 8040669 .   Pubmed ID: 8040669

  70. Mastorakos G, Chrousos G, Weber J. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993 Dec;77(6):1690-1694. Pubmedid: 8263159 .   Pubmed ID: 8263159

  71. Rosenberg S, Anderson W, Blaese M, Hwu P, Yannelli J, Yang J, TopalianSL, Schwartzentruber D, Weber J, Ettinghausen S, et a. The development of gene therapy for the treatment of cancer. Ann Surg. 1993 Oct;218(4):455-463. Pubmedid: 8215637 .   Pubmed ID: 8215637

  72. Weber J, Yang J, Topalian S, Parkinson D, Schwartzentruber D, Ettinghausen S, Gunn H, Mixon A, Kim H, Cole D, et a. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993 Mar;11(3):499-506. Pubmedid: 7680375 .   Pubmed ID: 7680375

  73. Weber J, Yang J, Topalian S, Schwartzentruber D, White D, RosenbergSA. The use of interleukin-2 and lymphokine-activated killer cells for thetreatment of patients with non-Hodgkin's lymphoma. J Clin Oncol. 1992 Jan;10(1):33-40. Pubmedid: 1727923 .   Pubmed ID: 1727923

  74. Karpati R, Banks S, Malissen B, Rosenberg S, Sheard M, Weber J, HodesRJ. Phenotypic characterization of murine tumor-infiltrating T lymphocytes. J Immunol. 1991 Mar;146(6):2043-2051. Pubmedid: 1672340 .   Pubmed ID: 1672340

  75. Fox B, Spiess P, Kasid A, Puri R, Mule J, Weber J, Rosenberg S. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod. 1990 Oct;9(5):499-511. Pubmedid: 2174966 .   Pubmed ID: 2174966

  76. Weber J, Rosenberg S. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst. 1990 May;82(9):755-761. Pubmedid: 2109092 .   Pubmed ID: 2109092

  77. Feltner D, Cooper M, Weber J, Israel M, Thiele C. Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene. J Immunol. 1989 Dec;143(12):4292-4299. Pubmedid: 2687378 .   Pubmed ID: 2687378

  78. Weber J, Rosenberg S. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988 Oct;48(20):5818-5824. Pubmedid: 3139284 .   Pubmed ID: 3139284

  79. Weber J, Jay G, Tanaka K, Rosenberg S. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med. 1987 Dec;166(6):1716-1733. Pubmedid: 3500265 .   Pubmed ID: 3500265

  80. Weber J, Blanchard J, Ginsberg H, Darnell JE J. Order of polyadenylic acid addition and splicing events in early adenovirusm RNA formation. J Virol. 1980 Jan;33(1):286-291. Pubmedid: 6245233 .   Pubmed ID: 6245233

  81. Wall R, Weber J, Gage Z, Darnell J. Production of viral mRNA in adenovirus- transformed cells by the post-transcriptional processing of heterogeneous nuclear RNA containing viral and cell sequences. J Virol. 1973 Jun;11(6):953-960. Pubmedid: 4736534 .   Pubmed ID: 4736534

  82. Weber JS. From the guest editor: introduction for immunotherapy of cancer. Cancer J. 16(4):294. Pubmedid: 20693838.   Pubmed ID: 20693838

  83. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance?. Cancer J. 16(4):311-317. Pubmedid: 20693841.   Pubmed ID: 20693841

Jeffrey S. Weber, MD, PhD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Phase II Study of YM155 Plus Docetaxel in Pts with Stage III Unresectable or Stage IV Melanoma
Sponsor: Astellas Pharma, Inc.
Project Dates: December 26, 2009 to December 25, 2011
Earned to Date: $101,919

Ipilimumab PK Process Study in Unresectable Stage III or Stage IV Melanoma
Sponsor: Bristol Myers Squibb Company
Project Dates: July 24, 2009 to July 23, 2011
Earned to Date: $174,582

Effect of Ipilimub on the PK of Chemotx and Effect of Chemotx on the PK Ipilimub in Melanoma
Sponsor: Bristol Myers Squibb Company
Project Dates: May 11, 2009 to May 10, 2011
Earned to Date: $139,808

Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III/IV Melanoma

BMS 734016
Sponsor: Bristol Myers Squibb Company
Project Dates: November 2, 2007 to November 1, 2010
Annual Direct Cost: $18,461
Annual Total Cost: $24,000
Project Total: $161,500

Phase I/II Study of Dasatanib and Dacarbazine
Sponsor: Bristol Myers Squibb Company
Project Dates: October 25, 2007 to October 24, 2010
Annual Direct Cost: $64,849
Annual Total Cost: $84,304
Project Total: $291,824

Phase II Study of Imatinib in Pts with Mucosal or Acral/lentiginous Melanoma
Sponsor: Dana-Farber Cancer Institute
Project Dates: July 18, 2009 to July 17, 2011
Earned to Date: $15,000

Phase II Trial Evaluating Bevacizumab in Combo with Carboplatin & Paclitaxel for Metastatic Melanoma

AVF4096g
Sponsor: Genentech, Inc.
Project Dates: May 26, 2007 to May 25, 2012
Annual Direct Cost: $452
Annual Total Cost: $588
Project Total: $24,842

Open Label Dose Esc Study of BRAF Inhibitor GSK 2118436 and MEK Inhibitor GSK 1120212 in Braf Melanoma
Sponsor: GlaxoSmithKline
Project Dates: February 18, 2010 to February 17, 2012
Earned to Date: $30,130

Trial of recMAGE-A3 + AS15 in pts with unresectable MAGE-A3 positive metastatic cutaneous melanoma
Sponsor: GlaxoSmithKline
Project Dates: October 26, 2009 to October 25, 2011
Earned to Date: $10,126

Donald A. Adam Comprehensive Melanoma Research Center (CMRC)
Sponsor: Moffitt Fdtn
Project Dates: January 1, 2010 to December 31, 2011
Annual Direct Cost: $275,000
Annual Total Cost: $275,000
Project Total: $522,748

CD40 and TLR Agonists in Melanoma

5 R21 CA135621-02
Sponsor: Nat Institutes of Health / NCI
Project Dates: July 1, 2009 to June 30, 2011
Annual Direct Cost: $220,000
Annual Total Cost: $331,582
Project Total: $734,800

PD-1 Abrogation and Immunity in Melanoma

5 R01 CA129594-02
Sponsor: Nat Institutes of Health / NCI
Project Dates: February 9, 2009 to December 31, 2013
Annual Direct Cost: $208,627
Annual Total Cost: $329,064
Project Total: $675,936

Open Label Study of Continuous Oral Dosing of RO5185426 in Previously Treated Pts with Metastatic Melanoma
Sponsor: Roche
Project Dates: October 14, 2009 to October 13, 2011
Earned to Date: $86,805

PD-1 Abrogation and Immunity in Melanoma (NO COST EXTENSION)

1 R01 FD003511-01
Sponsor: US Food & Drug Administration
Project Dates: September 1, 2009 to August 31, 2013

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute